1. Home
  2. RVPH vs RFL Comparison

RVPH vs RFL Comparison

Compare RVPH & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • RFL
  • Stock Information
  • Founded
  • RVPH 2006
  • RFL N/A
  • Country
  • RVPH United States
  • RFL United States
  • Employees
  • RVPH 15
  • RFL N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • RFL Real Estate
  • Sector
  • RVPH Health Care
  • RFL Finance
  • Exchange
  • RVPH Nasdaq
  • RFL Nasdaq
  • Market Cap
  • RVPH 36.4M
  • RFL 36.1M
  • IPO Year
  • RVPH N/A
  • RFL N/A
  • Fundamental
  • Price
  • RVPH $1.19
  • RFL $1.42
  • Analyst Decision
  • RVPH Strong Buy
  • RFL
  • Analyst Count
  • RVPH 3
  • RFL 0
  • Target Price
  • RVPH $14.33
  • RFL N/A
  • AVG Volume (30 Days)
  • RVPH 161.2K
  • RFL 23.5K
  • Earning Date
  • RVPH 08-12-2024
  • RFL 06-14-2024
  • Dividend Yield
  • RVPH N/A
  • RFL N/A
  • EPS Growth
  • RVPH N/A
  • RFL N/A
  • EPS
  • RVPH N/A
  • RFL N/A
  • Revenue
  • RVPH N/A
  • RFL $540,000.00
  • Revenue This Year
  • RVPH N/A
  • RFL N/A
  • Revenue Next Year
  • RVPH N/A
  • RFL N/A
  • P/E Ratio
  • RVPH N/A
  • RFL N/A
  • Revenue Growth
  • RVPH N/A
  • RFL 92.86
  • 52 Week Low
  • RVPH $1.05
  • RFL $1.29
  • 52 Week High
  • RVPH $6.80
  • RFL $2.52
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 48.81
  • RFL 50.98
  • Support Level
  • RVPH N/A
  • RFL N/A
  • Resistance Level
  • RVPH $1.35
  • RFL $1.47
  • Average True Range (ATR)
  • RVPH 0.09
  • RFL 0.07
  • MACD
  • RVPH -0.01
  • RFL -0.05
  • Stochastic Oscillator
  • RVPH 88.15
  • RFL 91.61

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.

Share on Social Networks: